An 8-hour phase advance, simulated jet lag disorder study of Tasimelteon

Trial Profile

An 8-hour phase advance, simulated jet lag disorder study of Tasimelteon

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 08 Nov 2017 According to a Vanda Pharmaceuticals media release, this study was initiated in October 2017 and is expected to be fully enrolled by the end of 2017. Results are expected in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top